ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Are molecular markers just for NSCLC?"
Episode Synopsis
Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.
More episodes of the podcast GRACEcast Bladder Cancer Video
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
31/07/2014
Management of Rare Kidney Tumors
29/07/2014
NanoString Treatment for Kidney Cancer
24/07/2014
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
22/07/2014
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17/07/2014
What is PD1 and PDL1 in Kidney Cancer?
15/07/2014
In God we trust